Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

60 THE PREMENSTRUAL SYNDROMES
PMS will contribute to reducing the healthcare costs
that are incurred by the large numbers of women who
seek medical care for this distressing disorder.
REFERENCES
1. Halbreich U, Borenstein J, Pearlstein T et al. The prevalence,
impairment, impact, and burden of premenstrual dysphoric
disorder (PMS/PMDD). Psychoneuroendocrinology 2003;
28:1–23.
2. Andersch B, Wenderstam C, Hahn L et al. Prevalence of premenstrual
symptoms in a Swedish urban population. J Psychosom
Obstet Gynaecol 1986; 5:39–49.
3. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual
symptoms in a nonclinical sample. I. Prevalence, natural
history and help-seeking behavior. J Reprod Med 1988;
33:340–6.
4. Wittchen HU, Becker E, Lieb R et al. Prevalence, incidence and
stability of premenstrual dysphoric disorder in the community.
Psychol Med 2002; 32:119–32.
5. Steiner M, Macdougall M, Brown E. The premenstrual symptoms
screening tool (PSST) for clinicians. Arch Womens Ment Health
2003; 6:203–9.
6. Cohen LS, Soares CN, Otto MW et al. Prevalence and predictors
of premenstrual dysphoric disorder (PMDD) in older premenopausal
women. The Harvard Study of Moods and Cycles. J Affect Disord
2002; 70:125–32.
7. Sveindottir H, Backstrom T. Prevalence of menstrual cycle
symptom cyclicity and premenstrual dysphoric disorder in a
random sample of women using and not using oral contraceptives.
Acta Obstet Gynecol Scand 2000; 79:405–13.
8. Angst J, Sellaro R, Merikangas KR et al. The epidemiology of perimenstrual
psychological symptoms. Acta Psychiatr Scand 2001;
104:110–16.
9. Sveinsdottir H, Lundman B, Norberg A. Women’s perceptions of
phenomena they label premenstrual tension: normal experiences
reflecting ordinary behaviour. J Adv Nurs 1999; 30:916–25.
10. Steiner M, Pearlstein T, Cohen LS et al. Expert guidelines for the
treatment of severe PMS, PMDD, and comorbidities: the role of
SSRIs. J Womens Health (Larchmt) 2006; 15:57–69.
11. Bloch M, Schmidt PJ, Rubinow DR. Premenstrual syndrome: evidence
for symptom stability across cycles. Am J Psychiatry 1997;
154:1741–6.
12. Eriksson E. Serotonin reuptake inhibitors for the treatment
of premenstrual dysphoria. Int Clin Psychopharmacol 1999;
14:S27–33.
13. Eriksson E, Andersch B, Ho H-P et al. Premenstrual dysphoria: an
illustrative example of how serotonin modulates sex-steroid-related
behavior. CNS Spectr 2001; 6:141–9.
14. Landen M, Eriksson E. How does premenstrual dysphoric disorder
relate to depression and anxiety disorders? Depress Anxiety
2003; 17:122–9.
15. Vickers K, McNally RJ. Is premenstrual dysphoria a variant of
panic disorder? A review. Clin Psychol Rev 2004; 24:933–56.
16. Dimmock PW, Wyatt KM, Jones PW et al. Efficacy of selective
serotonin-reuptake inhibitors in premenstrual syndrome: a systematic
review. Lancet 2000; 356:1131–6.
17. Wyatt KM, Dimmock PW, O’Brien PM. Selective serotonin reuptake
inhibitors for premenstrual syndrome. Cochrane Database
Syst Rev 2002; 4:CD001396.
18. Endicott J, Amsterdam J, Eriksson E et al. Is premenstrual dysphoric
disorder a distinct clinical entity? J Womens Health Gend
Based Med 1999; 8:663–79.
19. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically
and selectively increase brain neurosteroid content at
doses that are inactive on 5-HT reuptake. Psychopharmacology
2006; 186:362–72.
20. Freeman EW, Rickels K, Sondheimer SJ et al. Continuous or intermittent
dosing with sertraline for patients with severe premenstrual
syndrome or premenstrual dysphoric disorder. Am J Psychiatry
2004; 161:343–51.
21. Freeman EW, Rickels K, Sondheimer SJ et al. Differential response
to antidepressants in women with premenstrual syndrome/
premenstrual dysphoric disorder: a randomized controlled trial.
Arch Gen Psychiatry 1999; 56:932–9.
22. Brown CS, Ling FW, Andersen RN et al. Efficacy of depot leuprolide
in premenstrual syndrome: effect of symptom severity and
type in a controlled trial. Obstet Gynecol 1994; 84:779–86.
23. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing
hormone agonist in treatment of premenstrual symptoms with and
without ongoing dysphoria: a controlled study. Psychopharmacol
Bull 1997; 33:303–9.
24. Pearlstein TB, Stone AB, Lund SA. Comparison of fluoxetine,
bupropion, and placebo in the treatment of premenstrual dysphoric
disorder. J Clin Psychopharmacol 1997; 17:261–6.
25. Eriksson E, Hedberg A, Andersch B, Sundblad C. The serotonin
reuptake inhibitor paroxetine is superior to the noradrenaline
reuptake inhibitor maprotiline in the treatment of premenstrual
syndrome. Neuropsychopharmacology 1995; 12:167–76.
26. Taghavi E, Menkes DB, Howard RC et al. Premenstrual syndrome:
a double-blind controlled trial of desipramine and
metylscopolamine. Int Clin Psychopharmacol 1995; 10:119–22.
27. Yonkers KA, Barnett LK, Carmody T et al. Serial discontinuation
of SSRI treatment for PMDD. Biol Psychiatry 1998; 43:1S–133S.
28. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late
luteal phase dysphoric disorder. J Clin Psychiatry 1994; 55:332–5.
29. Elks ML. Open trial of fluoxetine therapy for premenstrual syndrome.
South Med J 1993; 86:503–7.
30. Freeman EW, Sondheimer SJ, Rickels K et al. A pilot naturalistic
follow-up of extended sertraline treatment for severe premenstrual
syndrome. J Clin Psychopharmacol 2004; 24:351–3.
31. Brown WJ, Doran FM. Women’s health: consumer views for planning
local health promotion and health care priorities. Aust N Z
J Public Health 1996; 20:149–54.
32. Singh BB, Berman BM, Simpson RL et al. Incidence of premenstrual
syndrome and remedy usage: a national probability sample
study. Altern Ther Health Med 1998; 4:75–9.
33. Corney RH, Stanton R. A survey of 658 women who report
symptoms of premenstrual syndrome. J Psychosom Res 1991;
35:471–82.
34. Campbell EM, Peterkin D, O’Grady K et al. Premenstrual symptoms
in general practice patients: prevalence and treatment.
J Reprod Med 1997; 42:637–46.
35. Freeman EW, Rickels K, Schweizer E et al. Relationships
between age and symptom severity among women seeking
medical treatment for premenstrual symptoms. Psychol Med
1995; 25:309–15.
36. Hurt SW, Schnurr PP, Severino SK et al. Late luteal phase dysphoric
disorder in 670 women evaluated for premenstrual complaints.
Am J Psychiatry 1992; 149:525–30.
37. Freeman EW, Sammel MD, Rinaudo PJ et al. Premenstrual syndrome
as a predictor of menopausal symptoms. Obstet Gynecol
2004; 103:960–6.
38. Richards M, Rubinow DR, Daly RC et al. Premenstrual symptoms
and perimenopausal depression. Am J Psychiatry 2006;
163:133–7.
39. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of
the relationship between reproductive status and mood in perimenopausal
women. Am J Psychiatry 2004; 161:2238–44.